Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Kidney & urinary clinical trials.
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to your bones or other organs, and it got worse while you were taking a medicine called abiraterone acetate (Zytiga).
- You have not received certain other treatments for your prostate cancer, like chemotherapy (except docetaxel if it worked well), other anti-androgen drugs (like enzalutamide, darolutamide, or apalutamide), targeted radiation therapy (like Pluvicto), or other experimental drugs.
- You are in good enough health to carry out daily activities with little or no help (ECOG 0 or 1), and your organs are working well enough.
- You do not have cancer that has spread to your brain or the lining around your brain and spinal cord.
- You do not have a serious heart condition, active infection, or a stomach problem that would affect taking oral medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This early-phase trial tests ORIC-944 to see how well it works and what dose is safest for metastatic prostate cancer that has progressed after hormone-targeted pills. It may help people whose cancer has stopped responding to prior prostate cancer hormone treatments.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.